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The labeled amino acid 6-[lsP]fluoro-L-3,4dihydroxyphenylalanine (esp]PDOPA) is employed as a tracer of the enzyme aromatic amino acid de carboxylase (AAAD) in positron emission tomogra phy (PET) studies of the human brain (Garnett et aI. , 1983; CaIne et aI. , 1985; Gjedde et aI., 1991; Kuwabara et aI. , 1992) . In PET studies employing [lsp]PDOPA, subjects usually receive oral carbi dopa 90 min before the tracer in order to inhibit the decarboxylation of [lsp] PDOPA in the periph-in close agreement with the actual concentrations deter mined by HPLC fractionation. Population means for ko (0.011 ± 0.002 min-I ) and L I (0.010 ± 0. 003 min-I ) were used to generate "simulated" plasma curves. The measured and generated plasma curves were used as in puts for estimation of partition and decarboxylation co efficients of [18F1FDOPA in brain. The use of generated input functions from normal population means of transfer coefficients did not introduce a systematic error into the estimate of the enzyme activity. However, the high vari ability of these estimates in patients precludes the use of this technique as an alterative to individual HPLC mea surements. ery. In carbidopa-pretreated subjects, circulating eSp]PDOPA is rapidly metabolized by catechol O-methyltransferase (COMT) to O-Methyl [lsp]PDOPA (OMe-esP]PDOPA), which pene trates the blood-brain barrier more readily then the parent compound (Reith et aI. , 1990) . Kinetic mod els for the estimation of cerebral AAAD activity therefore require the fractionation of plasma in or der to determine the relative amounts of esp] PDOPA and its principal metabolite (Gjedde et aI. , 1991; Huang et aI. , 1991) . However, the pharma cokinetics of eSp]PDOPA with respect to minor plasma metabolites has not previously been de scribed.
Time series for the plasma concentrations of eSp]PDOPA and its metabolites can be fitted to lin ear differential equations described the respective coefficients of formation (ko) and clearance (k _ I) of a metabolite (Gjedde et aI. , 1991) . The present study consists in a retrospective reanalysis of 28 PET studies, in which the coefficients were deter-mined for OMe-esF]FDOPA only, and the analysis of 20 new studies in which coefficients were deter mined for two trace metabolites also. The popula tion means for these rates were used to generate plasma metabolite curves for each subject. The par tition volume of [lsF]FDOPA (Ve) in frontal cortex and the relative AAAD (�) activity in caudate and putamen were calculated using input functions from HPLC data and from the generated blood curves. Additional plasma curves were generated using val ues of ko and k _ 1 which varied from the population means by ± 1 SD. The effect of these manipulations on estimation of cerebral uptake and metabolism in the populations were determined.
MATERIALS AND METHODS

HPLC analysis
In the plasma metabolism studies, subjects were either normal adults (n = 18) or patients undergoing treatment for epilepsy (n = 11), Parkinson's disease (n = 8), or schizophrenia (n = 11). Except for one normal control, each subject was administered 100 mg oral carbidopa (Merck) 90 min before the intravenous injection of [ I SFj _ FDOPA (3-5 mCi). Arterial blood samples were collected 30 times during the 90 min after tracer injection. Follow ing a brief centrifugation, total I SF activity was deter mined in plasma using a well counter (Canberra). Twelve plasma samples at times from 2.5-90 min were selected for HPLC analysis. Portions of these samples (0.4 ml) were added to a half volume of cold 1 M perchloric acid (BDH), mixed with a vortex, placed on ice for at least 15 min, and centrifuged for 10 minutes at 12,000 g. Super natants (100 fl.l) were analyzed by isocratic reversed phase HPLC on a 4-m spherical CI S column (4.4 x 125 mm, Serva) with an aqueous mobile phase (1.5 ml/min) containing 75 mM sodium phosphate (Fisher) adjusted to pH 2.9 with 60% perchloric acid to which was added 1 mM EDTA (Aldrich), 1 mM octylsulfonic acid (Sigma) and 9-12% (v/v) methanol (Fisher). Radioactivity in the eluent was determined by on-line gamma ray detection (Berthold).
Data analysis
The areas of radiochromatographic peaks correspond ing to [lsF]FDOPA, OMe-[ I SFjFDOPA and two other compounds (X and Y) were determined by HPLC frac tionation, and corrected for decay of the later-eluting peaks. The fraction of each compound relative to total plasma activity was calculated as a function of time. Time-activity curves were generated for each compound using total arterial activity curves and the fractions mea sured by HPLC, with linear interpolation for fractions at times not fractionated by HPLC.
The rate of change in the concentration of a metabolite following first-order kinetics can be described by a set of linear compartmental equations with only two parameters corresponding to the rates of formation and clearance (ko and L I ; Gjedde et aI., 1991; Huang et aI., 1991) . The derivation and extension of these equations is presented in the Appendix.
Log l o transformations of calculated plasma eSFj PDOP A concentrations at times after 20 min indicated first-order kinetics for net clearance (not shown, but see Fig. 4 ). This fractional rate constant was greater than the sum of the formation rates of the three [lsF]FDOPA me tabolites by a quantity presumably due to the clearance of [ IS PjFDOPA itself ( k 1"�OPA ) .
PET scans
We reanalyzed previously published data (Kuwabara et aI. , 1992) from 12 normal controls (45 ± 15 years old) and seven patients with Parkinson's disease (58 ± 9 years old) acquired with the Scanditronix PC-2048 15B PET camera. These studies had been performed in accordance with the Ethics and Research Review Committee of the Montreal Neurological Institute and Hospital. All subjects, save one normal control, had been pretreated with carbidopa (100 mg, oral) 90 min before the intravenous injection of 4-5 mCi [lsF]FDOPA. All patients had been withdrawn from medication for at least 12 h and suffered locomotor disability of 4-5 on the Hoehn and Yahr scale (1967) .
In the original analysis, time series of eSp]FDOPA and OMe-[lsF]FDOPA determined by HPLC fractionation were used as the input functions for the estimation of the tracer distribution volume (Ve) in the frontal cortex. The relative AAAD activity (�) was calculated in caudate and putamen, with Ve fixed to the value estimated for frontal cortex (Kuwabara et aI. , 1992) .
In the new analysis, time series for pSF]FDOPA and OMe-[ I SFjFDOPA concentrations in arterial plasma were generated on the basis of the measured total arterial plasma radioactivity and the population means of the ko and k _ I for PSFjPDOPA and its metabolites, based upon equations described in the Appendix. Other sets of plasma curves were generated using values of ko and k _ I which varied by ± 1 SD from the population means. New estimates of Ve and kr; were calculated from the gener ated plasma curves and compared with those from the original HPLC analyses.
RESULTS
Fractionation of plasma samples yielded the rel ative proportions of eSF]FDOPA, the principal me tabolite OMe-[lsF]FDOPA, and two minor com pounds. Metabolite X, eluting just before eSF] FDOPA, was detected in all subjects, and metabo lite Y, eluting between eSF]FDOPA and OMe eSF]FDOPA, was detected in 12 of 20 SUbjects. The kinetic analyses of the formation and clearance of three [lsF]FDOPA plasma metabolites are illus trated for a typical carbidopa treated subject ( Fig.  IA) and a normal subject without carbidopa (Fig.  IB) . The mean kinetic rate constants determined in normal volunteers and patients are summarized in Table I . Although the dominant metabolic process in plasma from carbidopa-pretreated subjects is de scribed by kiJI, the two minor [lsF]FDOPA metab olites were formed at measurable rates in most sub jects. The individual values for 00 and kJ correlated with each other (r = 0.4; n = 20; p < 0.05), but not with the values for kiJI.
Coefficients for the rate of formation of OMe- Linear regression slopes yield the clearance coefficients of compounds: k'-1 1 ' k': 1 , and k� 1 , whereas the ordi nate intercepts yield the coefficients of the rate of formation from C8F] FDOPA; k�, k�, and k'6. eSF]FDOPA (ki)'f) did not correlate with the age of the subjects ( Fig. 2A) , whereas the coefficients of clearance (J!'! I ) did indicate a significant decline with age within the normal group (Fig. 2B) . The mean values for the control group did not differ significantly from the values for the clinical groups (Table 1 ). Figure 2 also illustrates the reproducibil ity of separate triplicate determinations conducted with four parkinsonian subjects (SEM < 10%).
'
Coefficients for the clearance of eSF]FDOPA (k��OPA) and its metabolites X (� I ) and Y (k� I )
were plotted as afunction of age ( Fig. 3 ). Of these, only � 1 underwent a significant decline as a func tion of age. There was no significant effects of age or clinical status on the mean rates of formation of the three [lsF]FDOPA metabolites (Table 1 ). In the single study of a normal subject without carbidopa, ki)I (0.0090 min -I ) was close to the mean value for the other subjects, whereas 00 (0.010 min -I ) and k6 (0.0027 min -I ) were more than three times the pop ulation means determined for carbidopa-treated sub jects.
The measured arterial concentrations of eSF] FDOPA, OMe-esF]FDOPA, and the sum of the two minor labeled metabolites (X + Y) in a typical normal subject were compared with data generated from the individual estimates of ko and k _ 1 illus trated in Fig. 4 . The estimates of partition volume in frontal cortex (Ve), based on individual HPLC data, were in very close agreement with estimates based upon plasma curves generated using population means of ko and k_ 1 (Fig. 5) , as were the two sep arate estimates of /I.j (Fig. 6 ). The effect of varying population means of ko and k _ 1 by ± 1 SD on the variance of estimates of Ve and kP is shown in Ta ble 2. PET studies employing eSF]FDOPA are based on the assumption that the tracer is metabolized in a manner similar to L-DOPA itself. Indeed, the rat brain AAAD does not kinetically distinguish the two substrates (Cumming et aI. , 1988) . It is the for mation of 6-esF]-fluorodopamine (esF]FDA) by AAAD in the terminals of dopamine neurons that is responsible for the increased retention of radioac tivity in rat striatum relative to brain areas with low AAAD activity (Cumming et aI. , 1987a) .
PET studies with eSF]FDOPA are complicated by its rapid metabolism to OMe-esF]FDOPA, cat alyzed by COMT (Boyes et aI. , 1986) in peripheral organs. The O-methylated compound is taken up readily into rat brain (Reith et aI. , 1990) and is the predominant labeled compound in most areas of rat ��D(k., FDOPA)
Rate constants for the clearance of ['8F]FDOPA and two trace metabolites (X and Y) from plasma as a function of age (k��OPA, k�" and k",), The rate for the clear ance of compound X underwent a significant decline with age of the population (k�, = 3.8 X 10-2 min-1 -3.5 x 10-4 min-1 /year, p < 0.025), but the other rates did not vary with age, nor did the coefficients of formation (data not shown). Age (years)
... ... x + y 80 (Cumming et a!., 1987a; Melega et ai., 1990a) and monkey brain (Melega et ai., 1991) at 1 hour after tracer injection. The present rate constants for the formation and clearance of OMe-e8P]PDOPA agree closely with the corresponding rates which can be calculated from an earlier study in which cynomolgus mon keys received L-DOPA i.v. , and are also close to the rates reported in previous studies of [18p]PDOPA metabolism in hu mans (Gjedde et ai., 1991; Huang et a!., 1991) . The present in vivo study did not indicate a decline in COMT activity in humans with age, in agreement with limited ex vivo data (Guldberg and Marsden, 1975) . The COMT activity was not elevated in the patients with Parkinson's disease as a group, al- though one patient had very high activity in three separate determinations (Pig. 2), suggesting that in dividual variation may be more important than drug treatment history.
The cerebral synthesis of e8P]fluorodopamine e8p]PDA is limited, in part, by the availability of unmetabolized precursor during the PET experi ment. Because the formation of dopamine O-sul fate, the major plasma metabolite of L-DOPA in hu mans (Goodall and Alton, 1972; Jenner and Rose, 1974) , depends on AAAD, blockade of this enzyme with peripherally acting carbidopa increases the availability of L-DOPA in the circulation of patients undergoing treatment (Doller et a!., 1978) . Simi larly, most PET studies with e8p]PDOPA require carbidopa. In these cases, peripheral metabolism is 
0.00 largely restricted to O-methylation (Melega et aI. , 1990b) . In addition, studies in rats, monkeys, and humans have shown that blockade of COMT further decreases the peripheral metabolism of the tracer and thus increases its brain availability and striatal decarboxylation (Cumming et aI. , 1978b; Leger et aI. , 1990; Laihinen et aI. , 1992; Guttman et aI. , un published) . In order to quantify PET images, it is necessary to distinguish the signal in brain due to the entrap ment of locally decarboxylated compounds from the contribution of OMe-esP]PDOPA entering from the periphery. MuIticompartment models incorpo rating the uptake of both eSp]PDOPA and the prin cipal peripheral metabolite OMe-esP]PDOPA per mit the calculation of rate constants for the regional activities of AAAD (kP ; Gjedde et aI. , 1991; Huang et aI. , 1991) . Por such models, plasma samples must be fractionated in order to determine the propor tions of the labeled species circulating during the PET scan. Clearly, as the present study suggests, the radiochemical composition of plasma in carbi dopa-pretreated subjects receiving eSp]PDOPA is complex.
The positive correlation between individual val ues of kif and k� suggest that these two rates are a function of related processes. The lack of correla tion of these rates with Iq;t indicates that these mi nor processes are unrelated to the activity of COMT.
Although present methods cannot identify with certainty the two minor metabolites, a polar com pound eluting just before eSp]PDOPA, presumably corresponding to metabolite X in the present study, has been previously identified as eSp]PDA-sulfate (Cumming et aI. , 1987a; Melega et aI. , 1990a,b) . Purthermore, in our subject not pretreated with car bidopa, the apparent rates 00 and k� were some threefold higher than the population means from carbidopa-treated subjects, suggesting that metabo lites X and Y may be formed via decarboxylase. In human subjects receiving levodopa, 20-30% of pe ripheral AAAD activity remained after carbidopa pretreatment (Bianchine et aI. , 1973; Ward et aI. , 1984) . Higher doses of carbidopa might block pe ripheral AAAD completely, at the risk of also inter fering with cerebral decarboxylation (Da Prada et aI. , 1987) .
Clearance rates for three of the four ISp com pounds in circulation were close to 0.01 min -1 , but the clearance rate 0.. 1 was 0.023 min -1 (Table O. Although metabolite X is formed at 30% of the rate of OMe-esP]PDOPA formation in carbidopa pretreated subjects (Table 1) , the fraction of plasma radioactivity as metabolite X is lessened by the rel atively rapid clearance. Together, the metabolites X and Y constitute some 20% of total plasma radioac tivity at late times (Pig. 4). These compounds, pre sumably eSp]PDA metabolites, are unlikely to en ter brain and contribute to the PET signal (Doudet et aI., 1991) , but their presence should nonetheless be considered in calculations of the eSp]FDOPA input function.
Clearance rates for It! 1 and � 1 decline as a func tion of age, as might be expected for processes de pendent on renal function. The apparent half-lives of these declines are both close to 60 years. The relative SD of k � 1 was high because the small amounts of metabolite Y were difficult to quantify, whereas the relative SD of k��OPA was high because of propagation of error from the other clearance rates. The greater relative error in determinations of k��OPA and k� 1 may account for the lack of mea surable age effect on these rates.
Plasma eSp]PDOPA metabolism is here de scribed in terms of four compartments and seven rate constants. We have shown that the plasma me tabolite profile for a particular PET subject can be reconstructed from individual estimates of the ki netic parameters and from the time series of total arteriallsp activity. The time series calculated from the measured rate constants are in close agreement with the original HPLC data (Pig. 4).
The variance of the estimates of ki)1 and k� 1 within single subjects was less than 10% (Pig. 2). The population variation is comparable in order of magnitude to the variation of determinations within individuals ( Table 1 ). The use of population means of ko and k _ 1 was without systematic effect on the estimated values of Ve in cortex (Fig. 5 ), or of k� in striatum (Pig. 6). Neither did these approximations impair the ability of the PET study to distinguish regional � values of Parkinson's disease from nor mal values. However, the deviation (root mean square %) of cerebral influx and decarboxylation rates estimated using population means of ko and k -I were unacceptably large ( Table 2) . Estimations of � in the clinical group were especially sensitive to changes in the generated plasma curves, possibly because ko rates in some members of the clinical group differed greatly from the popUlation mean. Therefore, the present study suggests that HPLC fractionation remains indispensable for the confi dent estimation of eSp]PDOPA metabolism, pend ing a more complete description of the variability in peripheral metabolism.
First, the concentration of the precursor is predicted from the equation derived from the sum of the three equa tions above, i.e., from the sum of the individual metabo lites subtracted from the total radioactivity concentra tion, C FDOPA = Ct -k o e-(k-l+ko)T IO T Cte(k-I+ko) t dt (5) where 1.0 = �k� is the sum of the individual rates of gen eration of each metabolite, k_l the single rate of elimina tion applied to all metabolites, and C , the total radioac tivity concentration in plasma.
Secondly, when C FDOPA has been estimated, the indi vidual metabolite concentrations were predicted from the equations,
These equations represent the individual solutions of differential Eq. (1). The uncertainty of the prediction was evaluated by adding noise to the rate constant estimates by varying the value of each estimate by ± 1 SD from the mean.
